Goldman Sachs Physical Gold ETF vs Novavax Inc — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.46, while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Goldman Sachs Physical Gold ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| AAAU | NVAX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $11.19 |
52-Week Low | $32.74 | $6.22 |
Market Cap | — | $1.31B |
Enterprise Value | — | $889.30M |
Signals from Pluang's Aura AI — not financial advice
AAAU trades at $43.42, up 0.35% today, with a bullish technical signal from moving averages but bearish oscillators. Key support is at $42 and resistance at $44. Recent news highlights gold's strength amid cooling U.S. inflation and geopolitical tensions, with spot gold reaching $4,438/oz. Financial ratios are unavailable, limiting fundamental assessment.
The outlook for AAAU is supported by positive gold market dynamics, including central bank demand and inflation trends. Risks include potential Fed policy shifts and market volatility. Analyst sentiment is mixed, with technical indicators suggesting caution despite bullish momentum.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Trailing returns across standard periods
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →